References

Antonia, Scott J, José A López-Martin, Johanna Bendell, Patrick A Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, et al. 2016. “Nivolumab Alone and Nivolumab Plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate 032): A Multicentre, Open-Label, Phase 1/2 Trial.” The Lancet Oncology 17 (7): 883–95.

Gheorghiade, Mihai, Stephen J Greene, Javed Butler, Gerasimos Filippatos, Carolyn SP Lam, Aldo P Maggioni, Piotr Ponikowski, et al. 2015. “Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients with Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.” Jama 314 (21): 2251–62.

Guo, Wentian, Sue-Jane Wang, Shengjie Yang, Henry Lynn, and Yuan Ji. 2017. “A Bayesian Interval Dose-Finding Design addressingOckham’s Razor: mTPI-2.” Contemporary Clinical Trials 58: 23–33.

Ji, Yuan, Ping Liu, Yisheng Li, and B Nebiyou Bekele. 2010. “A Modified Toxicity Probability Interval Method for Dose-Finding Trials.” Clinical Trials 7 (6): 653–63.

Jing, Naimin, Fang Liu, Heng Zhou, Cong Chen, et al. 2022. “An Optimal Two-Stage Exploratory Basket Trial Design with Aggregated Futility Analysis.” Contemporary Clinical Trials 116: 106741.

Jung, Sin-Ho, Taiyeong Lee, KyungMann Kim, and Stephen L George. 2004. “Admissible Two-Stage Designs for Phase II Cancer Clinical Trials.” Statistics in Medicine 23 (4): 561–69.

Li, Pin, Rachael Liu, Jianchang Lin, and Yuan Ji. 2020. “TEPI-2 and UBI: Designs for Optimal Immuno-Oncology and Cell Therapy Dose Finding with Toxicity and Efficacy.” Journal of Biopharmaceutical Statistics 30 (6): 979–92.

Lin, Ruitao, and Guosheng Yin. 2017. “STEIN: A Simple Toxicity and Efficacy Interval Design for Seamless Phase i/II Clinical Trials.” Statistics in Medicine 36 (26): 4106–20.

Lin, Ruitao, Yanhong Zhou, Fangrong Yan, Daniel Li, and Ying Yuan. 2020. “Boin12: Bayesian Optimal Interval Phase i/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.” JCO Precision Oncology 4: 1393–1402.

Lin, Xiaolei, and Yuan Ji. 2021. “Probability Intervals of Toxicity and Efficacy Design for Dose-Finding Clinical Trials in Oncology.” Statistical Methods in Medical Research 30 (3): 843–56.

Liu, Suyu, and Ying Yuan. 2015. “Bayesian Optimal Interval Designs for Phase i Clinical Trials.” Journal of the Royal Statistical Society: Series C (Applied Statistics) 64 (3): 507–23.

Simon, Richard. 1989. “Optimal Two-Stage Designs for Phase II Clinical Trials.” Controlled Clinical Trials 10 (1): 1–10.

Takeda, Kentaro, Masataka Taguri, and Satoshi Morita. 2018. “BOIN-ET: Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes.” Pharmaceutical Statistics 17 (4): 383–95.

Wu, Xiaoqiang, Cai Wu, Fang Liu, Heng Zhou, and Cong Chen. 2021. “A Generalized Framework of Optimal Two-Stage Designs for Exploratory Basket Trials.” Statistics in Biopharmaceutical Research 13 (3): 286–94.

Zhou, Heng, Fang Liu, Cai Wu, Eric H Rubin, Vincent L Giranda, and Cong Chen. 2019. “Optimal Two-Stage Designs for Exploratory Basket Trials.” Contemporary Clinical Trials 85: 105807.